"Unequivocally Abnormal" vs "Usual" Signs and Symptoms for Proficient Diagnosis of Diabetic Polyneuropathy: Cl vs N Phys Trial - PubMed (original) (raw)
. 2012 Dec;69(12):1609-14.
doi: 10.1001/archneurol.2012.1481.
Carol J Overland, Phillip A Low, William J Litchy, Jenny L Davies, P James B Dyck, Rickey E Carter, L Joseph Melton, Henning Andersen, James W Albers, Charles F Bolton, John D England, Christopher J Klein, Gareth Llewelyn, Michelle L Mauermann, James W Russell, Dinesh Selvarajah, Wolfgang Singer, A Gordon Smith, Solomon Tesfaye, Adrian Vella
- PMID: 22986424
- PMCID: PMC3570730
- DOI: 10.1001/archneurol.2012.1481
"Unequivocally Abnormal" vs "Usual" Signs and Symptoms for Proficient Diagnosis of Diabetic Polyneuropathy: Cl vs N Phys Trial
Peter J Dyck et al. Arch Neurol. 2012 Dec.
Abstract
OBJECTIVE To repeat the Clinical vs Neurophysiology (Cl vs N Phys) trial using "unequivocally abnormal" signs and symptoms (Trial 2) compared with the earlier trial (Trial 1), which used "usual" signs and symptoms. DESIGN Standard and referenced nerve conduction abnormalities were used in both Trials 1 and 2 as the standard criterion indicative of diabetic sensorimotor polyneuropathy. Physician proficiency (accuracy among evaluators) was compared between Trials 1 and 2. SETTING Academic medical centers in Canada, Denmark, England, and the United States. PARTICIPANTS Thirteen expert neuromuscular physicians. One expert was replaced in Trial 2. RESULTS The marked overreporting, especially of signs, in Trial 1 was avoided in Trial 2. Reproducibility of diagnosis between days 1 and 2 was significantly (P = .005) better in Trial 2. The correlation of the following clinical scores with composite nerve conduction measures spanning the range of normality and abnormality was improved in Trial 2: pinprick sensation (P = .03), decreased reflexes (P = .06), touch-pressure sensation (P = .06), and the sum of symptoms (P = .06). CONCLUSIONS The simple pretrial decision to use unequivocally abnormal signs and symptoms-taking age, sex, and physical variables into account-in making clinical judgments for the diagnosis of diabetic sensorimotor polyneuropathy (Trial 2) improves physician proficiency compared with use of usual elicitation of signs and symptoms (Trial 1); both compare to confirmed nerve conduction abnormality.
Conflict of interest statement
Conflict of Interest Disclosures: None reported.
Figures
Figure 1
The clothing, masks, and dark glasses used to disguise the identity of patients (only 12 of the 24 patients are seen in the front row). The voices of patients were electronically altered. Patients did not speak unless physicians wore earphones. Some study personnel are also shown.
Figure 2
The frequency of at least 75% of expert physicians’ elicitation of signs, symptoms, and clinical diagnosis of diabetic sensorimotor polyneuropathy. Confirmed nerve conduction (NC) abnormality (calculated as the composite standard normal deviate score of 5 attributes of NC abnormality [Σ 5 NC nds ≤2.5th percentile]) is compared with results on days 1 and 2 of the Cl vs N Phys Trial 1 (A) and Trial 2 (a replication of Trial 1) (B). Percentages are calculated from 576 physician evaluations for 24 patients. Ellipses indicate not applicable. *Overreported clinical diagnoses were defined as the presence of clinical abnormalities but no NC abnormalities.
Similar articles
- Proficiency of nerve conduction using standard methods and reference values (Cl. NPhys Trial 4).
Litchy WJ, Albers JW, Wolfe J, Bolton CF, Walsh N, Klein CJ, Zafft AJ, Russell JW, Zwirlein M, Overland CJ, Davies JL, Carter RE, Dyck PJ; CI. Nphys Trial 4 Investigators. Litchy WJ, et al. Muscle Nerve. 2014 Dec;50(6):900-8. doi: 10.1002/mus.24243. Epub 2014 Oct 30. Muscle Nerve. 2014. PMID: 24644133 Free PMC article. - The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial.
Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, Low PA, Nehrdich D, Novosadova M, O'Brien PC, Reljanovic M, Samigullin R, Schuette K, Strokov I, Tritschler HJ, Wessel K, Yakhno N, Ziegler D; SYDNEY Trial Study Group. Ametov AS, et al. Diabetes Care. 2003 Mar;26(3):770-6. doi: 10.2337/diacare.26.3.770. Diabetes Care. 2003. PMID: 12610036 Clinical Trial. - Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy.
Dyck PJ, Karnes JL, Daube J, O'Brien P, Service FJ. Dyck PJ, et al. Brain. 1985 Dec;108 ( Pt 4):861-80. doi: 10.1093/brain/108.4.861. Brain. 1985. PMID: 4075076 - Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.
England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT, Cohen JA, Fisher MA, Howard JF, Kinsella LJ, Latov N, Lewis RA, Low PA, Sumner AJ; American Academy of Neurology; American Association of Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. England JD, et al. Neurology. 2005 Jan 25;64(2):199-207. doi: 10.1212/01.WNL.0000149522.32823.EA. Neurology. 2005. PMID: 15668414 Review. - Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity.
Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels GJ, Bril V, Feldman EL, Litchy WJ, O'Brien PC, Russell JW; Toronto Expert Panel on Diabetic Neuropathy. Dyck PJ, et al. Diabetes Metab Res Rev. 2011 Oct;27(7):620-8. doi: 10.1002/dmrr.1226. Diabetes Metab Res Rev. 2011. PMID: 21695763 Review.
Cited by
- Composite nerve conduction scores and signs for diagnosis and somatic staging of diabetic polyneuropathy: Mid North American ethnic cohort survey.
Davies JL, Lodermeier KA, Klein DM, Carter RE, Dyck PJB, Litchy WJ, Dyck PJ. Davies JL, et al. Muscle Nerve. 2023 Jul;68(1):29-38. doi: 10.1002/mus.27793. Epub 2023 Mar 1. Muscle Nerve. 2023. PMID: 36734298 Free PMC article. - Evidence-Based Treatment of Painful Diabetic Neuropathy: a Systematic Review.
D'Souza RS, Barman R, Joseph A, Abd-Elsayed A. D'Souza RS, et al. Curr Pain Headache Rep. 2022 Aug;26(8):583-594. doi: 10.1007/s11916-022-01061-7. Epub 2022 Jun 18. Curr Pain Headache Rep. 2022. PMID: 35716275 Review. - mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin-mediated amyloidosis.
Dyck PJB, Kincaid JC, Wiesman JF, Polydefkis M, Litchy WJ, Mauermann ML, Ackermann EJ, Guthrie S, Pollock M, Jung SW, Baker BF, Dyck PJ. Dyck PJB, et al. Muscle Nerve. 2020 Oct;62(4):502-508. doi: 10.1002/mus.27022. Epub 2020 Aug 13. Muscle Nerve. 2020. PMID: 32654212 Free PMC article. Clinical Trial. - Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis.
Dyck PJB, Coelho T, Waddington Cruz M, Brannagan TH 3rd, Khella S, Karam C, Berk JL, Polydefkis MJ, Kincaid JC, Wiesman JF, Litchy WJ, Mauermann ML, Ackermann EJ, Baker BF, Jung SW, Guthrie S, Pollock M, Dyck PJ. Dyck PJB, et al. Muscle Nerve. 2020 Oct;62(4):509-515. doi: 10.1002/mus.27023. Epub 2020 Aug 7. Muscle Nerve. 2020. PMID: 32654156 Free PMC article. Clinical Trial. - Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.
Adams D, Suhr OB, Dyck PJ, Litchy WJ, Leahy RG, Chen J, Gollob J, Coelho T. Adams D, et al. BMC Neurol. 2017 Sep 11;17(1):181. doi: 10.1186/s12883-017-0948-5. BMC Neurol. 2017. PMID: 28893208 Free PMC article. Clinical Trial.
References
- Gilliatt RW. Clinical aspects of diabetic neuropathy. In: Cumings JN, Kremer M, editors. Biochemical Aspects of Neurological Disorders. Oxford, England: Blackwell; 1965. pp. 117–142.
- Pirart J. Diabetic neuropathy: a metabolic or a vascular disease? Diabetes. 1965;14:1–9. - PubMed
- Nilsson SV, Nilsson JE, Frostberg N, Emilsson T. The Kristianstad survey, II: studies in a representative adult diabetic population with special reference to comparison with an adequate control group. Acta Med Scand Suppl. 1967;469:1–42. - PubMed
- Franklin GM, Kahn LB, Baxter J, Marshall JA, Hamman RF. Sensory neuropathy in non–insulin-dependent diabetes mellitus: the San Luis Valley Diabetes Study. Am J Epidemiol. 1990;131(4):633–643. - PubMed
- England JD, Gronseth GS, Franklin G, et al. American Academy of Neurology; American Association of Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2005;64(2):199–207. - PubMed